Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Germing

Showing results (311-320 of 339) with videos related to

Pageof 34
Sort By:
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Wiener Klinische Wochenschrift|July 20, 2019
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical researchKlaus Geissler, Eva Jäger, Agnes Barna, et al.
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
The New England Journal of Medicine|November 26, 2024
Aggressive Lymphoma after CD19 CAR T-Cell TherapyGuido Kobbe, Monika Brüggemann, Ben-Niklas Baermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Haematologica|June 24, 2009
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesArjan A van de Loosdrecht, Canan Alhan, Marie Christine Béné, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.
Pageof 34

Showing results (311-320 of 339) with videos related to

Sort By:
Pageof 34
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Wiener Klinische Wochenschrift|July 20, 2019
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical researchKlaus Geissler, Eva Jäger, Agnes Barna, et al.
BMC Cancer|September 24, 2022
The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromesTamara K Moyo, Jason H Mendler, Raphael Itzykson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2017
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating AgentsSophie Park, Jean-François Hamel, Andrea Toma, et al.
The New England Journal of Medicine|November 26, 2024
Aggressive Lymphoma after CD19 CAR T-Cell TherapyGuido Kobbe, Monika Brüggemann, Ben-Niklas Baermann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2024
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic SyndromesCristina Astrid Tentori, Caterina Gregorio, Marie Robin, et al.
Blood|February 1, 2023
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromesAmer M Zeidan, Uwe Platzbecker, Jan Philipp Bewersdorf, et al.
Haematologica|June 24, 2009
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesArjan A van de Loosdrecht, Canan Alhan, Marie Christine Béné, et al.
Blood|July 29, 2024
Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletionMaria Julia Montoro, Laura Palomo, Claudia Haferlach, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.
Pageof 34